| Name | Title | Contact Details |
|---|
Jewish Home Of Rochester is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Community Health Resources` (CHR) mission is to help adults, children and families find Real Hope for the challenges of Real Life through an array of community based mental health, substance use, child welfare, supported housing, foster care, prevention and wellness services and integrated care. Our name embodies our commitment to community based care, utilizing all available resources to achieve change, and instill hope for a healthy, happy and productive future. CHR is proud to provide services that achieve Real Quality with Real Results. CHR’s history dates back to the 1960s, and since its creation, has become a trusted community resource and well-respected service provider. We employ over 700 experienced staff members who provided services to more than 18,000 individuals in the past year. We offer effective, accesible and affordable behavioral healthcare through 80 programs and 32 locations. As we anticipate changing needs, we will offer new programs, recruit exceptional staff, collaborate with other providers, and explore new funding sources. The driving force of our growth continues to be meeting the needs of those we serve.
Frontline Dental Implant Specialists (FDIS) is a dental implant partnership network that brings together top dental implant specialists with over 150+ years of combined experience.
CellASIC Corp. is a San Leandro, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.